---
schema_version: "secwatch.filing_event.v1"
accession: "0001846253-24-000071"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:17:12.767523+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OmniAb Q2 revenue $7.6M, net loss $0.13/sh; guides 2024 opex slightly below 2023

## Summary
- Q2 2024 revenue $7.6M (+10% YoY), net loss $13.6M ($0.13/sh) vs $14.7M loss in Q2 2023.
- H1 2024 revenue $11.4M vs $23.9M (prior year included $10M TECVAYLI milestone); net loss $32.6M ($0.32/sh).
- Cash $57.2M at June 30; expects 2024 opex slightly below 2023, cash use similar to 2023 ex-$35M milestone.
- New platform licenses with DAAN Bio, Topaz Therapeutics, HanAll Biopharma; post-Q2 deals with 92Bio and Memorial Sloan Kettering.
- GSK discontinued Nav1.1 program (OmniAb retains co-ownership); Roche returning Kv7.2 rights (not due to scientific reasons).

## SEC filing metadata
- accession: 0001846253-24-000071
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000184625324000071/0001846253-24-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000184625324000071/oabi-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001846253-24-000071
- JSON: https://secwatch.observer/filing/0001846253-24-000071.json
- Plain text: https://secwatch.observer/filing/0001846253-24-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.